Abstract
The HIV-1 nucleocapsid protein NCp7, which contains two highly conserved zinc fingers, is being used as a novel target for AIDS therapy due to its pivotal role in viral replication and its mutationally intolerant nature. Herein we report a new class of NCp7 inhibitors that possess good antiviral activity with low cellular toxicity.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Anti-HIV Agents / chemical synthesis*
-
Anti-HIV Agents / pharmacology
-
Benzamides / chemistry*
-
Capsid / antagonists & inhibitors*
-
Capsid Proteins*
-
Cell Survival / drug effects
-
Cells, Cultured
-
Gene Products, gag / antagonists & inhibitors*
-
HIV Infections / drug therapy
-
HIV-1 / drug effects*
-
HIV-1 / physiology
-
Humans
-
Monocytes / drug effects
-
Structure-Activity Relationship
-
Thiocarbamates / chemical synthesis*
-
Thiocarbamates / pharmacology
-
Tumor Necrosis Factor-alpha / pharmacology
-
Viral Proteins*
-
Zinc Fingers
-
gag Gene Products, Human Immunodeficiency Virus
Substances
-
Anti-HIV Agents
-
Benzamides
-
Capsid Proteins
-
Gene Products, gag
-
NCP7 protein, Human immunodeficiency virus 1
-
Thiocarbamates
-
Tumor Necrosis Factor-alpha
-
Viral Proteins
-
gag Gene Products, Human Immunodeficiency Virus